Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Hypertension in 2016

Blood pressure goals, variability and SGLT2 blockade in CKD

Nature Reviews Nephrology volume 13, pages 75–76 (2017)Cite this article

Subjects

Blood pressure (BP) goals and the management of BP in patients with chronic kidney disease (CKD) remain controversial topics. Key articles in the past year have addressed BP goals in CKD, the use of new agents to slow CKD progression and the effects of visit-to-visit variability in systolic BP on cardiovascular events and renal progression in patients with CKD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Peralta, C. A. et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch. Intern. Med. 172, 41–47 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  2. James, P. A. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507–520 (2014).

    Article  CAS  PubMed  Google Scholar 

  3. Ambrosius, W. T. et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin. Trials 11, 532–546 (2014).

    Article  PubMed  Google Scholar 

  4. Wright, J. T. Jr. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).

    Article  CAS  PubMed  Google Scholar 

  5. Xie, X. et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387, 435–443 (2016).

    Article  PubMed  Google Scholar 

  6. Cooper-DeHoff, R. M. & Johnson, J. A. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat. Rev. Nephrol. 12, 110–122 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).

    Article  CAS  PubMed  Google Scholar 

  8. Diaz, K. M. et al. Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis. Hypertension 64, 965–982 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Chang, T. I. et al. Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. J. Hum. Hypertens. 28, 18–24 (2014).

    Article  CAS  PubMed  Google Scholar 

  10. Chang, T. I., Tabada, G. H., Yang, J., Tan, T. C. & Go, A. S. Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease. J. Hypertens. 34, 244–252 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Electrolyte and Hypertension Division, Renal, Perelman School of Medicine at the University of Pennsylvania, 1 Founders Building, 3400 Spruce Street, Philadelphia, 19104, USA

    Debbie L. Cohen & Raymond R. Townsend

Authors
  1. Debbie L. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond R. Townsend
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Debbie L. Cohen or Raymond R. Townsend.

Ethics declarations

Competing interests

D.L.C. and R.R.T. are SPRINT study investigators.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cohen, D., Townsend, R. Blood pressure goals, variability and SGLT2 blockade in CKD. Nat Rev Nephrol 13, 75–76 (2017). https://doi.org/10.1038/nrneph.2016.189

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2016.189

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing